Spark Therapeutics Inc said it plans to seek marketing approval in the US next year for a gene therapy following a Phase 3 trial in which the experimental treatment helped restore vision to patients with an inherited eye disorder. ---Subscribe to MedNous to access this article--- Company News Regenerative Medicine Clinical Research
